Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology
Contemplate a private placement of NOK 125–150 million to fund the combined business
Oslo, (11 June 2015): Targovax AS (“Targovax” or the “Company”) has entered into an agreement with the shareholders of Oncos Therapeutics Oy (“Oncos”) to acquire the shares of Oncos with settlement in Targovax shares (the “Transaction”). The combined company with multiple assets in research and development will be a Nordic leader within immuno-oncology. The new company will have a strong senior management team and be financially backed by reputable institutional investors with sector specialist HealthCap